Want to see ATHE full AI Analyst Report?
Top Page
Alterity Therapeutics
(NASDAQ:ATHE)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
â–Ľ(-0.88% Downside)
Action:Reiterated
Date:07/07/26
The score is primarily held back by weak financial performance (persistent losses and negative cash flows) despite low leverage. Technicals are supportive with a clear uptrend, but momentum indicators point to overbought conditions. Valuation is difficult to justify with a negative P/E and no dividend data.
Positive Factors
Regulatory de-risking (FDA pathway for ATH434)
FDA End-of-Phase 2 minutes confirm a clear registrational pathway and endorse a single pivotal Phase 3 plus confirmatory evidence for ATH434. This materially reduces regulatory uncertainty, focuses program design and resources, and shortens the path-to-approval risk profile over the next 2-6 months.
Negative Factors
Negative operating and free cash flow
Ongoing negative operating and free cash flows mean the business burns cash to fund R&D and operations. For a clinical-stage biotech preparing a pivotal Phase 3, persistent negative cash generation creates durable funding needs, heightening dilution and execution risk until commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory de-risking (FDA pathway for ATH434)
FDA End-of-Phase 2 minutes confirm a clear registrational pathway and endorse a single pivotal Phase 3 plus confirmatory evidence for ATH434. This materially reduces regulatory uncertainty, focuses program design and resources, and shortens the path-to-approval risk profile over the next 2-6 months.
Read all positive factors
Alterity Therapeutics (ATHE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$80.67M
Dividend YieldN/A
Average Volume (3M)13.05K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue GrowthN/A
EPS Growth32.81%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.96
Shares Outstanding18,140,840
10 Day Avg. Volume16,981
30 Day Avg. Volume13,055
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.56
Price to Sales (P/S)12.18
P/FCF Ratio-5.79
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue20.40
Enterprise Value/Gross Profit21.07
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$12.67Price Target Upside179.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$4.21M
Alterity Therapeutics Business Overview & Revenue Model
Company Description
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent e...
How the Company Makes Money
null...
Alterity Therapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.83M | 5.44M | 4.02M | 3.92M | 5.12M | 4.34M |
| Gross Profit | 3.71M | 5.31M | 3.80M | 3.63M | 4.76M | 3.98M |
| EBITDA | -19.87M | -14.63M | -19.57M | -14.60M | -17.39M | -15.16M |
| Net Income | -14.41M | -12.15M | -19.12M | -13.81M | -12.85M | -15.31M |
Balance Sheet | ||||||
| Total Assets | 56.86M | 46.03M | 19.22M | 27.32M | 41.36M | 33.59M |
| Cash, Cash Equivalents and Short-Term Investments | 49.15M | 40.66M | 12.64M | 15.77M | 34.81M | 28.12M |
| Total Debt | 98.35K | 155.46K | 159.04K | 210.38K | 117.49K | 65.65K |
| Total Liabilities | 2.65M | 3.62M | 5.43M | 4.50M | 5.89M | 3.12M |
| Stockholders Equity | 54.21M | 42.40M | 13.80M | 22.81M | 35.47M | 30.47M |
Cash Flow | ||||||
| Free Cash Flow | -2.36M | -11.45M | -12.61M | -20.04M | -12.43M | -17.34M |
| Operating Cash Flow | -12.78M | -11.45M | -12.61M | -20.04M | -12.34M | -17.33M |
| Investing Cash Flow | -137.62K | -7.50M | -5.72K | -36.46K | -89.15K | -10.47K |
| Financing Cash Flow | 44.09M | 39.67M | 9.22M | 124.34K | 16.30M | 36.69M |
Alterity Therapeutics Technical Analysis
Negative
4.54
Price Trends
4.67
Negative
4.35
Positive
3.96
Positive
Market Momentum
-0.01
Positive
41.25
Neutral
10.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATHE, the sentiment is Negative. The current price of 4.54 is below the 20-day moving average (MA) of 4.97, below the 50-day MA of 4.67, and above the 200-day MA of 3.96, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.25 is Neutral, neither overbought nor oversold. The STOCH value of 10.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATHE.
Alterity Therapeutics Risk Analysis
Alterity Therapeutics disclosed 44 risk factors in its most recent earnings report. Alterity Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alterity Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $80.67M | -6.65 | -30.19% | ― | ― | 32.81% | |
45 Neutral | $21.32M | -0.33 | -221.50% | ― | ― | 71.62% | |
44 Neutral | $75.96M | -1.63 | -72.78% | ― | ― | 73.91% | |
43 Neutral | $141.51M | -2.44 | -131.18% | ― | ― | -36.64% |
* Healthcare Sector Average
ATHE
Alterity Therapeutics
4.42
-0.59
-11.88%
CVM
Cel-Sci
1.16
-8.29
-87.72%
XBIT
XBiotech
2.23
-0.62
-21.75%
RPTX
Repare Therapeutics
2.65
1.15
76.67%
KLRS
Kalaris Therapeutics
3.51
0.82
30.48%
UNCY
Unicycive Therapeutics
5.01
0.81
19.29%
Alterity Therapeutics Corporate Events
Alterity Therapeutics Secures FDA Pathway and Bolsters Funding for ATH434 Phase 3 in MSA
Jul 30, 2026
In the quarter ended 30 June 2026, Alterity Therapeutics secured key regulatory progress for its lead MSA candidate ATH434, with U.S. FDA End-of-Phase 2 meeting minutes confirming a clear registrational pathway. The agency indicated that a single ...
Alterity Therapeutics Files Form 6-K and Seeks Quotation for ATH Securities
Jul 21, 2026
On July 21, 2026, Alterity Therapeutics Limited filed a Form 6-K with the U.S. Securities and Exchange Commission, reporting as a foreign private issuer for the month of July 2026. The filing confirms the company continues to rely on existing Form...
Alterity Therapeutics CEO to Engage U.S. Investors at BTIG Biotechnology Conference 2026
Jul 21, 2026
Alterity Therapeutics announced on July 21, 2026, that Chief Executive Officer David Stamler, M.D., will participate in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29. During the event, Dr. Stamler plans to hold one-on-on...
Alterity Therapeutics Secures FDA-Confirmed Registrational Pathway for ATH434 in Multiple System Atrophy
Jul 7, 2026
On July 7, 2026, Alterity Therapeutics announced it has received official U.S. Food and Drug Administration End-of-Phase 2 meeting minutes confirming the registrational pathway for its lead drug candidate ATH434 in Multiple System Atrophy. The FDA...
Alterity Therapeutics Files July Form 6-K for Quotation of ATH Securities
Jul 1, 2026
On July 1, 2026, Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission, signaling an application for quotation of its securities under the ticker ATH. The filing, signed by Chairman Julian Babarczy, indicates the ...
Alterity Therapeutics Discloses Change in Substantial Shareholding in June 2026 SEC Filing
Jun 30, 2026
Alterity Therapeutics Limited reported a change in substantial holding in a Form 6-K filing with the U.S. Securities and Exchange Commission for June 2026, signed by Chairman Julian Babarczy on June 30, 2026. The disclosure, made via Exhibit 99.1,...
Alterity Therapeutics Files June 2026 Form 6-K Highlighting Changes in Directors’ Interests
Jun 17, 2026
Alterity Therapeutics reported on June 17, 2026, that it had filed a Form 6-K with the U.S. Securities and Exchange Commission as a foreign private issuer, updating its disclosure record for the month of June 2026. The filing primarily serves to l...
Alterity Therapeutics Files June 2026 Corporate Presentation With U.S. Regulator
Jun 16, 2026
Alterity Therapeutics on June 16, 2026, filed a Form 6-K with the U.S. Securities and Exchange Commission, indicating the submission of a new corporate presentation dated June 2026 as an exhibit. The filing, signed by Chairman Julian Babarczy, als...
Alterity Therapeutics Files Form 6-K on Unquoted Securities Notification
Jun 15, 2026
Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission on June 15, 2026, as a routine report for a foreign private issuer. The filing discloses the submission of a notification regarding unquoted securities under t...
Alterity Therapeutics Files June Form 6-K Highlighting Cessation of Certain Securities
Jun 15, 2026
Alterity Therapeutics Limited reported on June 15, 2026 that it had submitted a Form 6-K to the U.S. Securities and Exchange Commission for the month of June as a foreign private issuer. The filing incorporates the report by reference into several...
Alterity Therapeutics Completes 50-for-1 Capital Consolidation After Shareholder Approval
Jun 12, 2026
Alterity Therapeutics, listed on the ASX and Nasdaq, develops disease-modifying therapies for neurodegenerative disorders, notably Multiple System Atrophy, from bases in Melbourne and San Francisco. Its lead drug candidate ATH434 has produced posi...
Alterity Therapeutics Wins FDA Backing for Pivotal Phase 3 Program of ATH434 in Multiple System Atrophy
Jun 9, 2026
Alterity Therapeutics, which operates from Melbourne and San Francisco, is advancing a pipeline that centers on ATH434 for MSA, a rare and rapidly progressive Parkinsonian disorder with no approved disease-modifying therapies. Its Phase 2 program ...
Alterity Therapeutics Data Underpin Phase 3 Advancement of ATH434 in Multiple System Atrophy
May 19, 2026
On May 19, 2026, Alterity Therapeutics reported new clinical and imaging data for ATH434 in Multiple System Atrophy, presented across three medical conferences, which collectively support advancing the candidate to Phase 3 development. Analyses fr...
Alterity Therapeutics Files May 2026 Form 6-K, Releases New Corporate Presentation
May 12, 2026
On May 12, 2026, Alterity Therapeutics filed a Form 6-K with the U.S. Securities and Exchange Commission for the month of May as a foreign private issuer. The filing incorporates certain existing registration statements by reference and primarily ...
Alterity Therapeutics Highlights MRI Biomarker Breakthrough as It Prepares Phase 3 MSA Program
May 11, 2026
On 11 May 2026, Alterity Therapeutics reported new peer-reviewed data in NeuroImage showing that quantitative susceptibility mapping MRI can identify disease-specific iron accumulation in Multiple System Atrophy, distinguish MSA from ParkinsonR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.